Incyte disclosed preliminary results for an experimental myelofibrosis agent that produced meaningful spleen-volume reductions and symptom improvements in advanced patients, according to ASH presentations. The drug targets calreticulin-mutant disease, an approach intended to diversify Incyte’s portfolio as Jakafi faces impending generic competition. Company commentary framed the dataset as supportive of continued development, noting that robust spleen responses are a standard regulatory and clinical benchmark in myelofibrosis trials.